---
title: "Navigating India’s Regulatory Landscape: The New Drugs and Clinical Trials Rules, 2019"
date: 2024-11-22
author: "Rahul Sundaram"
url: https://www.indialaw.in/blog/civil/india-regulatory-drug-clinical-trial/
---

# Navigating India’s Regulatory Landscape: The New Drugs and Clinical Trials Rules, 2019

Posted On - 22 November, 2024 •

By - [Rahul Sundaram](https://www.indialaw.in/people/rahul-sundaram/ "Posts by Rahul Sundaram")

[![Navigating India’s Regulatory Landscape: The New Drugs and Clinical Trials Rules](https://www.indialaw.in/wp-content/uploads/Bureau-of-Indian-Standards-BIS.jpg)](https://www.indialaw.in/wp-content/uploads/Bureau-of-Indian-Standards-BIS.jpg)

India’s pharmaceutical industry has long been a global leader, recognized for its innovation and contributions to improving healthcare accessibility. As the industry continues to grow, ensuring safety, ethical practices, and a robust regulatory framework becomes paramount. In response to these needs, the Ministry of Health and Family Welfare introduced the **New Drugs and Clinical Trials Rules, 2019**. These rules streamline the approval process for new drugs and clinical trials while safeguarding participant rights and maintaining high ethical standards.

## A Comprehensive Framework

## Ethics Committees: The Pillars of Integrity

At the heart of this regulatory structure are ethics committees, which oversee all clinical trials and biomedical research. These committees must include medical professionals, legal experts, laypersons, and independent members to ensure diverse perspectives in decision-making. Registration with the Central Licensing Authority (CLA) is mandatory, with validity granted for five years. By enforcing Good Clinical Practices (GCP), ethics committees are instrumental in protecting participants’ rights and well-being.

## Clinical Trials: Streamlining Innovation

The rules establish a clear process for initiating clinical trials, requiring prior approval from the CLA. Special provisions allow for expedited approvals for orphan drugs and therapies addressing life-threatening conditions, reflecting the government’s commitment to fostering innovation in healthcare.

The rules also ensure compensation mechanisms for trial-related injuries or deaths, ensuring accountability. Strict adherence to GCP guidelines underscores participant safety, and post-trial access to investigational drugs is mandated, benefiting patients who derive therapeutic value from experimental treatments.

## Regulating Manufacturing and Import

The manufacturing and importation of new drugs now require CLA approval. Specific exemptions are provided for investigational and orphan drugs, encouraging research into treatments for rare diseases.

## Bioavailability and Bioequivalence Studies

For generic drugs to enter the market, bioavailability (BA) and bioequivalence (BE) studies are essential. The rules regulate these studies, mandating ethics committee oversight to ensure safety and compliance.

## Compensation for Trial-Related Adverse Events

The rules impose clear obligations on sponsors to compensate participants for injuries or fatalities resulting from trials. The process for reporting serious adverse events (SAEs) is well-defined, requiring prompt communication with ethics committees, sponsors, and regulatory authorities.

## Enforcement and Monitoring

To maintain compliance, the CLA is empowered to inspect trial sites, manufacturing facilities, and ethics committees. Non-compliance can result in the suspension or cancellation of approvals, emphasizing the importance of adherence to these regulations.

## Importation of New Drugs

1. **Regulatory Requirement for Import**:

Any individual or entity wishing to import a new drug—whether as an active pharmaceutical ingredient or a finished formulation—must adhere to strict guidelines set forth by the regulatory authorities. Importation is prohibited unless the drug complies with the established rules and standards as specified by the governing Act.

1. **Application Process**:

To import a new drug, applicants must submit an application to the Central Licensing Authority (CLA). This application should be accompanied by the required documentation and the applicable fee. The submitted materials must include essential information about the drug, such as clinical data, safety reports, and approval status in other countries (if applicable).

1. **Conditions for Import Permission**:

Permission to import new drugs is granted under specific conditions. The drug must meet approved standards, and each consignment should include a test or analysis report confirming its compliance. Additionally, the drug’s labeling must follow regulatory guidelines, ensuring transparency and accurate information for consumers. Importers are also required to conduct ongoing post-marketing surveillance and submit Periodic Safety Update Reports (PSURs) to the authorities.

1. **Suspension or Cancellation of Import Permissions**:

If an importer fails to comply with regulatory requirements or if the imported drugs fail to meet safety or quality standards, the CLA has the right to suspend or cancel the permission for importation. This ensures that only drugs meeting safety and quality standards remain in the market.

## Manufacturing of New Drugs

1. **Manufacturing Permission**:

Similar to the importation process, the manufacturing of new drugs also requires prior approval from the CLA. Manufacturers must submit an application, accompanied by documentation detailing the manufacturing process, raw materials, safety data, and quality assurance protocols.

1. **Documentation and Compliance**:

Applications for manufacturing permission must include extensive documentation that confirms the drug’s safety, efficacy, and compliance with manufacturing standards. This includes clinical trial data, details of manufacturing facilities, and quality control procedures.

1. **Post-Approval Obligations**:

Once permission to manufacture is granted, manufacturers must ensure that all drugs produced adhere to the approved standards. Any changes to the drug’s composition, production process, or labeling must be reported to the authorities. Additionally, manufacturers must comply with any conditions stipulated by the regulatory authorities, including providing the necessary reports on the safety and efficacy of the drug during its market life.

## A Foundation for Ethical and Safe Innovation

The **New Drugs and Clinical Trials Rules, 2019** represent a progressive step in India’s pharmaceutical and healthcare landscape. By balancing the need for innovation with participant safety and ethical rigor, these rules create a conducive environment for research and development. As India continues to emerge as a global leader in pharmaceuticals, adherence to these regulations will ensure sustainable growth and reaffirm the country’s commitment to quality and safety in healthcare.

This regulatory framework not only fosters trust among stakeholders but also positions India as a benchmark for responsible pharmaceutical development.

For any further details, please contact us at [**contact@indialaw.in**](mailto:contact@indialaw.in).

---

# IndiaLaw LLP — Offices & Contact Details

---

## General Contact

| | |
|---|---|
| **Website** | https://www.indialaw.in |
| **Primary email** | contact@indialaw.in |
| **Primary phone** | +91 836-9995919 |
| **Contact form** | https://www.indialaw.in/connect/ |
| **Careers (separate channel)** | https://www.indialaw.in/careers/ |


---

## All Offices (9 locations across 8 cities)

### 1. Mumbai — Registered Office & Head Office (Apeejay Chambers)

| | |
|---|---|
| **Address** | Apeejay Chambers, Ground Floor, Wallace Street, Fort, Mumbai – 400 001 |
| **Phone** | [022-6924-7400](tel:02269247400) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/mumbai/ |
| **Practice focus** | Litigation · Arbitration · Insolvency & Bankruptcy · Corporate · Banking · Real Estate · IP |
| **Notes** | The HQ. 5 partners based here. Handles PAN-India litigation, arbitration, corporate, banking, IP and real estate practice. Largest team across all offices. |

### 2. Mumbai — Non-Litigation Office (Excelsior, Fort)

| | |
|---|---|
| **Address** | 4th Floor, New Excelsior Theatre Pvt. Ltd., Amrit Keshav Nayak Marg, Fort, Mumbai – 400 001 |
| **Phone** | [022-697-40500](tel:022-697-40500) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/mumbai/ |
| **Practice focus** | Non-litigation only — consultations, negotiations, transactional work |
| **Notes** | Opened 2024. Litigation and arbitration remain at the Apeejay Chambers head office. |

### 3. Delhi

| | |
|---|---|
| **Address** | Flat No. 1107 & 1108, Prakashdeep Building, Tolstoy Marg, Connaught Place, New Delhi – 110 001 |
| **Phone** | (general line: +91 836-9995919) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/delhi/ |
| **Practice focus** | Litigation · Arbitration · Insolvency & Bankruptcy · Corporate · Banking · Real Estate |
| **Notes** | 3 partners based here. Located near the Supreme Court of India, Delhi High Court and other appellate bodies. |

### 4. Kolkata

| | |
|---|---|
| **Address** | Centre Point Building, Room No. 214, 2nd Floor, Premises No. 21, Hemanta Basu Sarani, Opp. Great Eastern Hotel, P.S. Hare Street, Kolkata – 700 001, West Bengal |
| **Phone** | [+91 33 4813 1001](tel:+913348131001) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/kolkata/ |
| **Practice focus** | Insolvency & Bankruptcy · Commercial & Civil Litigation · Arbitration · Banking Litigation · Real Estate · Labour & Employment · Consumer |
| **Notes** | Advises banks, NBFCs, MSMEs and corporates on transactions and dispute resolution. Works in close coordination with the Mumbai HO. |

### 5. Chennai

| | |
|---|---|
| **Address** | GF-A, 19 Casa Major Road, Egmore, Chennai – 600 008 |
| **Phone** | (general line: +91 836-9995919) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/chennai/ |
| **Practice focus** | Litigation · Insolvency & Bankruptcy · Real Estate |
| **Notes** | Full-fledged office with experienced legal team. Supported by Mumbai HO. |

### 6. Bengaluru (Bangalore)

| | |
|---|---|
| **Address** | INDIALAW LLP, No. 7 Chinnaswamy Mudaliar Road, Shivaji Nagar, Bangalore – 560 051 |
| **Phone** | [080-4167-2444](tel:08041672444) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/bengaluru/ |
| **Practice focus** | Litigation · Insolvency & Bankruptcy · Real Estate · Family Laws · Labour |
| **Notes** | Located near Bangalore High Court. Handles corporate, commercial, banking and matrimonial disputes. |

### 7. Hyderabad

| | |
|---|---|
| **Address** | 403, 4th Floor, Sanatana Ecstasy Building, beside Tanishq Show Room, Himayathnagar, Hyderabad – 500 029, Telangana |
| **Phone** | [040-6666-5166](tel:04066665166) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/hyderabad/ |
| **Practice focus** | Litigation · Banking · Insolvency & Bankruptcy · Real Estate |
| **Notes** | Particularly well known for complex banking matters and real estate transactions. |

### 8. Cochin (Kochi)

| | |
|---|---|
| **Address** | Second Floor, Pulikkal Building, K.K. Padmanabhan Road, Ernakulam North – 682 018, Kerala |
| **Phone** | [0484-3583961](tel:04843583961) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/cochin/ |
| **Practice focus** | Litigation · Insolvency & Bankruptcy · Real Estate |
| **Notes** | Commercial disputes, property litigation, financial-claim arbitrations and real estate transactions. |

### 9. Noida (NCR)

| | |
|---|---|
| **Address** | No. 16 & 17, Silver Offices, 17th Floor, Wave One, Sector 18, Noida – 201 301 |
| **Phone** | (general line: +91 836-9995919) |
| **Email** | contact@indialaw.in |
| **Page** | https://www.indialaw.in/noida/ |
| **Practice focus** | Aviation · Insurance · Mergers & Acquisitions · Corporate |
| **Office head** | **Mr. Dinesh Gupta** (joined August 2025 to lead and expand the corporate practice) |
| **Notes** | Newest office. Sector-focused on highly regulated industries serving NCR-based clients. |

---

## Quick-Dial Phone List

| Office | Phone |
|---|---|
| Mumbai HO (Apeejay) | 022-6924-7400 |
| Mumbai Excelsior | 022-697-40500 |
| Kolkata | +91 33 4813 1001 |
| Bengaluru | 080-4167-2444 |
| Hyderabad | 040-6666-5166 |
| Cochin | 0484-3583961 |
| **General / Marketing line** | **+91 836-9995919** |

Delhi, Chennai and Noida route through the general number.

---

## Social Channels

- LinkedIn: https://www.linkedin.com/company/indialaw
- X / Twitter: https://twitter.com/Indialawmumbai
- Facebook: https://www.facebook.com/indialawllp/
- Instagram: https://www.instagram.com/indialawllp

---